Sunday, May 29, 2016

Nobilis Health strategy gains media attention

Nobilis Health strategy gains media attention

May 26, 2016 by · Leave a Comment 

Tweet Nobilis Health (NYSE MKT:HLTH; TSX:NHC) VP of Corporate Development, Kolin Ozonian, has been interviewed by The Life Sciences Report about the company’s strategy of managing both acquisitions and internal growth at the same time. In the interview, Mr. Ozonian discusses how Nobilis is orchestrating the flow of new patients to its ambulatory surgical centers while […]

BioSyent signs distribution pact for two CV products

BioSyent signs distribution pact for two CV products

May 25, 2016 by · Leave a Comment 

Tweet BioSyent (TSX-V:RX; OTC:BIOYF) has signed an exclusive distribution agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. […]

Delivra implementing U.S. expansion strategy for topical creams

Delivra implementing U.S. expansion strategy for topical creams

May 24, 2016 by · Leave a Comment 

Tweet The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through regional and national retailers, such as Walmart, Walgreens and CVS. “We are launching an aggressive digital campaign shortly, and later […]

FDA grants Profound Medical IDE approval for TULSA-PRO

FDA grants Profound Medical IDE approval for TULSA-PRO

May 19, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer. TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing […]

Profound Medical, Royal Phillips in TULSA-PRO sales pact

Profound Medical, Royal Phillips in TULSA-PRO sales pact

May 11, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac’]

Tweet Profound Medical (TSX-V:PRN) and Royal Philips have signed a sales and marketing agreement that will advance the commercial launch of Profound’s TULSA-PRO, a minimally invasive system to ablate targeted prostate tissue. Under the accord, the two companies will collaborate in the commercialization of TULSA-PRO in Europe followed by Canada, the U.S. and other markets, […]

Zomedica Pharma listed on TSX Venture

Zomedica Pharma listed on TSX Venture

May 2, 2016 by · Leave a Comment 

Tweet The shares of Zomedica Pharmaceuticals (TSX-V:ZOM), a veterinary pharmaceutical company, have been listed on TSX Venture Exchange under the symbol, ZOM. “With our shares trading on TSX-V, Zomedica has a more-efficient method for raising capital to bring our veterinarian-focused products to market while concurrently delivering liquidity for shareholders,” president and CEO, Gerald Solensky, Jr., […]

Nobilis Health launches bundled payment and technology unit

Nobilis Health launches bundled payment and technology unit

May 2, 2016 by · Leave a Comment 

Tweet Nobilis Health (NYSE MKT:HLTH; TSX:NHC) has launched a comprehensive technology platform that will develop new payment and delivery methodologies to enhance value for patients, payers, and providers across the continuum of care. The new unit will be called, Concertis, and will be headed by Marissa Arreola, a former health law partner at the firm […]

GeneNews closes note financing with Alumina

GeneNews closes note financing with Alumina

April 28, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has executed a definitive financing agreement with Alumina Partners for a second tranche of a non-brokered private placement. Under the accord, GeneNews will draw down on $10-million in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period. The initial draw will be limited to $200,000 […]

Novadaq posts 52% jump in Q1 revenue

Novadaq posts 52% jump in Q1 revenue

April 27, 2016 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago. Total direct sales in the quarter rose by $6.1-million, or 71%, and total partnered/international sales declined by $100,000, compared with the year earlier period. The company estimates that the number of procedures performed using SPY technology systems […]

Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics begins Phase 2 SARM study

April 26, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have […]

Next Page »

Email Newsletters with Constant Contact
Google+